BMRN – BioMarin Pharmaceutical Inc.
Float Short %
2.73
Margin Of Safety %
-8
Put/Call OI Ratio
0.55
EPS Next Q Diff
-0.29
EPS Last/This Y
2.05
EPS This/Next Y
1.15
Price
58.55
Target Price
98.2
Analyst Recom
1.47
Performance Q
0.98
Relative Volume
0.73
Beta
0.35
Ticker: BMRN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | BMRN | 59.01 | 0.69 | 0.33 | 29551 |
| 2025-07-28 | BMRN | 58.11 | 0.69 | 0.41 | 29560 |
| 2025-07-29 | BMRN | 58.21 | 0.69 | 0.15 | 29670 |
| 2025-07-30 | BMRN | 58.8 | 0.68 | 0.29 | 29824 |
| 2025-07-31 | BMRN | 57.85 | 0.68 | 2.14 | 29863 |
| 2025-08-01 | BMRN | 58.15 | 0.73 | 0.04 | 31579 |
| 2025-08-04 | BMRN | 60.35 | 0.72 | 0.23 | 31872 |
| 2025-08-05 | BMRN | 61.92 | 0.68 | 0.16 | 33249 |
| 2025-08-06 | BMRN | 60.65 | 0.65 | 0.37 | 34175 |
| 2025-08-07 | BMRN | 59.46 | 0.64 | 0.44 | 35043 |
| 2025-08-08 | BMRN | 57.33 | 0.63 | 0.10 | 36171 |
| 2025-08-11 | BMRN | 56.8 | 0.60 | 0.30 | 37413 |
| 2025-08-12 | BMRN | 56.84 | 0.57 | 0.10 | 38074 |
| 2025-08-13 | BMRN | 58.29 | 0.56 | 0.38 | 38592 |
| 2025-08-14 | BMRN | 58 | 0.57 | 0.31 | 38924 |
| 2025-08-15 | BMRN | 57.53 | 0.56 | 0.26 | 38975 |
| 2025-08-18 | BMRN | 57.44 | 0.57 | 0.17 | 33613 |
| 2025-08-19 | BMRN | 57.28 | 0.57 | 0.21 | 34031 |
| 2025-08-20 | BMRN | 57.94 | 0.56 | 0.08 | 34209 |
| 2025-08-21 | BMRN | 58.07 | 0.56 | 0.23 | 34412 |
| 2025-08-22 | BMRN | 58.66 | 0.55 | 0.15 | 34497 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | BMRN | 59.01 | 4.5 | 1.8 | 4.17 |
| 2025-07-28 | BMRN | 58.16 | 5.5 | 0.5 | 4.18 |
| 2025-07-29 | BMRN | 58.23 | 5.5 | 12.3 | 4.18 |
| 2025-07-30 | BMRN | 58.81 | 5.5 | 18.4 | 4.18 |
| 2025-07-31 | BMRN | 57.85 | 5.5 | -0.9 | 4.18 |
| 2025-08-01 | BMRN | 58.14 | 5.5 | 14.9 | 4.18 |
| 2025-08-04 | BMRN | 60.31 | 5.5 | 38.7 | 4.18 |
| 2025-08-05 | BMRN | 61.93 | 5.5 | 31.0 | 4.18 |
| 2025-08-06 | BMRN | 60.65 | -1.3 | -4.4 | 4.27 |
| 2025-08-07 | BMRN | 59.46 | -1.3 | -292.3 | 4.27 |
| 2025-08-08 | BMRN | 57.33 | -9.5 | -302.1 | 4.30 |
| 2025-08-11 | BMRN | 56.82 | -9.5 | -285.5 | 4.30 |
| 2025-08-12 | BMRN | 56.84 | -9.5 | -256.7 | 4.31 |
| 2025-08-13 | BMRN | 58.30 | -11.0 | -240.8 | 4.31 |
| 2025-08-14 | BMRN | 58.01 | -11.0 | -260.2 | 4.30 |
| 2025-08-15 | BMRN | 57.53 | -11.0 | -262.2 | 4.30 |
| 2025-08-18 | BMRN | 57.45 | -11.0 | -258.0 | 4.30 |
| 2025-08-19 | BMRN | 57.31 | -11.0 | -258.5 | 4.30 |
| 2025-08-20 | BMRN | 57.92 | -11.0 | -250.2 | 4.30 |
| 2025-08-21 | BMRN | 58.07 | -11.0 | -255.8 | 4.30 |
| 2025-08-22 | BMRN | 58.55 | -11.0 | -251.7 | 4.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | BMRN | -0.43 | 1.21 | 3.23 |
| 2025-07-28 | BMRN | -0.43 | 1.32 | 3.23 |
| 2025-07-29 | BMRN | -0.43 | 1.32 | 3.23 |
| 2025-07-30 | BMRN | -0.43 | 1.32 | 3.23 |
| 2025-07-31 | BMRN | -0.43 | 1.32 | 3.23 |
| 2025-08-01 | BMRN | -0.43 | 1.32 | 3.23 |
| 2025-08-04 | BMRN | -0.43 | 1.48 | 3.23 |
| 2025-08-05 | BMRN | -0.43 | 1.48 | 3.23 |
| 2025-08-06 | BMRN | -0.43 | 1.48 | 3.23 |
| 2025-08-07 | BMRN | -0.43 | 1.48 | 3.23 |
| 2025-08-08 | BMRN | -0.43 | 1.48 | 3.23 |
| 2025-08-11 | BMRN | -0.43 | 1.54 | 3.23 |
| 2025-08-12 | BMRN | -0.43 | 1.54 | 2.72 |
| 2025-08-13 | BMRN | -0.43 | 1.54 | 2.72 |
| 2025-08-14 | BMRN | -0.43 | 1.54 | 2.72 |
| 2025-08-15 | BMRN | -0.43 | 1.54 | 2.72 |
| 2025-08-18 | BMRN | -0.43 | 1.83 | 2.72 |
| 2025-08-19 | BMRN | -0.43 | 1.83 | 2.73 |
| 2025-08-20 | BMRN | -0.41 | 1.83 | 2.73 |
| 2025-08-21 | BMRN | -0.41 | 1.83 | 2.73 |
| 2025-08-22 | BMRN | -0.41 | 1.83 | 2.73 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.25
Avg. EPS Est. Current Quarter
0.81
Avg. EPS Est. Next Quarter
0.96
Insider Transactions
-0.41
Institutional Transactions
1.83
Beta
0.35
Average Sales Estimate Current Quarter
789
Average Sales Estimate Next Quarter
814
Fair Value
53.91
Quality Score
97
Growth Score
96
Sentiment Score
49
Actual DrawDown %
50.3
Max Drawdown 5-Year %
-53.9
Target Price
98.2
P/E
17.35
Forward P/E
12.75
PEG
0.52
P/S
3.7
P/B
1.87
P/Free Cash Flow
16.19
EPS
3.38
Average EPS Est. Cur. Y
4.3
EPS Next Y. (Est.)
5.45
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
21.62
Relative Volume
0.73
Return on Equity vs Sector %
-13.8
Return on Equity vs Industry %
-0.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-0.01
EBIT Estimation
-251.7
BioMarin Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 3040
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
stock quote shares BMRN – BioMarin Pharmaceutical Inc. Stock Price stock today
news today BMRN – BioMarin Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BMRN – BioMarin Pharmaceutical Inc. yahoo finance google finance
stock history BMRN – BioMarin Pharmaceutical Inc. invest stock market
stock prices BMRN premarket after hours
ticker BMRN fair value insiders trading